275 related articles for article (PubMed ID: 21509503)
21. The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.
Schaal SM; Garg MS; Ghosh M; Lovera L; Lopez M; Patel M; Louro J; Patel S; Tuesta L; Chan WM; Pearse DD
PLoS One; 2012; 7(9):e43634. PubMed ID: 23028463
[TBL] [Abstract][Full Text] [Related]
22. PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Kenk M; Thomas A; Lortie M; Dekemp R; Beanlands RS; Dasilva JN
Curr Radiopharm; 2011 Jan; 4(1):44-58. PubMed ID: 22191614
[TBL] [Abstract][Full Text] [Related]
23. Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases.
Leroy J; Abi-Gerges A; Nikolaev VO; Richter W; Lechêne P; Mazet JL; Conti M; Fischmeister R; Vandecasteele G
Circ Res; 2008 May; 102(9):1091-100. PubMed ID: 18369156
[TBL] [Abstract][Full Text] [Related]
24. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
[TBL] [Abstract][Full Text] [Related]
25. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
26. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice.
Thompson BE; Sachs BD; Kantak KM; Cherry JA
Eur J Neurosci; 2004 May; 19(9):2561-8. PubMed ID: 15128409
[TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.
Kuroiwa M; Snyder GL; Shuto T; Fukuda A; Yanagawa Y; Benavides DR; Nairn AC; Bibb JA; Greengard P; Nishi A
Psychopharmacology (Berl); 2012 Feb; 219(4):1065-79. PubMed ID: 21833500
[TBL] [Abstract][Full Text] [Related]
28. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Kanes SJ; Tokarczyk J; Siegel SJ; Bilker W; Abel T; Kelly MP
Neuroscience; 2007 Jan; 144(1):239-46. PubMed ID: 17081698
[TBL] [Abstract][Full Text] [Related]
29. PDE type-4 inhibition increases L-type Ca(2+) currents, action potential firing, and quantal size of exocytosis in mouse chromaffin cells.
Marcantoni A; Carabelli V; Vandael DH; Comunanza V; Carbone E
Pflugers Arch; 2009 Mar; 457(5):1093-110. PubMed ID: 18779976
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.
Totani L; Piccoli A; Dell'Elba G; Concetta A; Di Santo A; Martelli N; Federico L; Pamuklar Z; Smyth SS; Evangelista V
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1689-96. PubMed ID: 24925970
[TBL] [Abstract][Full Text] [Related]
31. Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.
Wachtel H
J Neural Transm; 1983; 56(2-3):139-52. PubMed ID: 6190991
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the significance of cyclic adenosine monophosphate-mediated signaling in human prostate: a functional and biochemical study.
Kedia GT; Ückert S; Polat H; Merseburger AS; Kuczyk MA
Urology; 2012 Oct; 80(4):952.e9-14. PubMed ID: 22901823
[TBL] [Abstract][Full Text] [Related]
33. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
34. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
35. Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.
Galindo-Tovar A; Kaumann AJ
Br J Pharmacol; 2008 Feb; 153(4):710-20. PubMed ID: 18084319
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effect of phosphodiesterase 4 inhibitor and serum on migration of endotoxin-stimulated macrophages.
Yang JX; Hsiung TC; Weng FC; Ding SL; Wu CP; Conti M; Chuang TH; Catherine Jin SL
Innate Immun; 2018 Nov; 24(8):501-512. PubMed ID: 30409089
[TBL] [Abstract][Full Text] [Related]
37. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus.
Fujimaki K; Morinobu S; Duman RS
Neuropsychopharmacology; 2000 Jan; 22(1):42-51. PubMed ID: 10633490
[TBL] [Abstract][Full Text] [Related]
38. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.
Kenk M; Greene M; Thackeray J; deKemp RA; Lortie M; Thorn S; Beanlands RS; DaSilva JN
Nucl Med Biol; 2007 Jan; 34(1):71-7. PubMed ID: 17210463
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of phosphodiesterase-4 in the spinal dorsal horn ameliorates neuropathic pain via cAMP-cytokine-Cx43 signaling in mice.
Zhang FF; Wang H; Zhou YM; Yu HY; Zhang M; Du X; Wang D; Zhang F; Xu Y; Zhang JG; Zhang HT
CNS Neurosci Ther; 2022 May; 28(5):749-760. PubMed ID: 35156776
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.
Galindo-Tovar A; Vargas ML; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 2009 Apr; 379(4):379-84. PubMed ID: 19005642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
